Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lactylome profiling of G2/M-synchronized sorafenib-resistant HepG2 cells using 4D DIA proteomics

ABSTRACT: This dataset contains lysine lactylation proteomics data generated from G2/M-synchronized sorafenib-resistant HepG2 cells using a 4D DIA LC-MS/MS workflow. Lactylated peptides were enriched and analyzed to characterize lactylation events associated with G2/M. The dataset provides a resource for identifying lactylated substrates in the context of cell cycle regulation.

ORGANISM(S): Homo Sapiens

SUBMITTER: Ping Xie

PROVIDER: PXD077426 | iProX | Tue Apr 21 00:00:00 BST 2026

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Similar Datasets

RNA seq data of sorafenib resistant HepG2 cells

Project description:To investigate the molecular mechanism of ferroptosis resistance in HCC, we applied sorafenib, one of the class I ferroptosis inducers (FINs), to generate HepG2 sorafenib resistant (SR) cells.

2024-02-03 | GSE248764 | GEO

Total RNAseq of HepG2 cells treated with Sorafenib

Project description:Total RNAseq of HepG2 cells treated with Sorafenib

| PRJNA936119 | ENA

RNA seq data of sorafenib resistant HepG2 cells

Project description:RNA seq data of sorafenib resistant HepG2 cells

| PRJNA1045966 | ENA

Total RNAseq of HepG2 cells treated with Sorafenib

Project description:Hepatocellular carcinoma (HCC) is one of the most common causes of death worldwide and the fourth most prevalent type of cancer. Whereas curative treatments such as liver transplantation, ablation or surgery are optimal for early stages, only paliative treatments are given to intermediate and advanced stages of the disease. Sorafenib is still a suitable therapeutic option for patients in whom immunotherapy is not feasible. To gain information about therapy response, we sequenced HepG2 cells treated with Sorafenib 10 µM (24 hours)

2023-12-01 | GSE225537 | GEO

Pooled CRISPR/Cas9 screen identifies chromatin regulatory genes mediating sorafenib resistance in HepG2 hepatocellular carcinoma cells

Project description:Focused pooled CRISPR/Cas9 screen in HepG2 HCC cells. ~6,000 sgRNAs targeting ~750 chromatin/TF genes (~800 non-targeting controls). 4 conditions: T0, DMSO, sorafenib 2.5 µM IC10, sorafenib 4 µM IC50; 3 replicates each. MAGeCK identified ARID1B among top sorafenib-resistance hits. Preprint: https://doi.org/10.64898/2026.06.11.731725

2026-06-19 | GSE335773 | GEO

Transcriptional profiling of sorafenib-resistant and parental sensitive HepG2 and Huh7 hepatocellular carcinoma cells

Project description:Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide, and acquired resistance to sorafenib—the first-line targeted therapy for advanced HCC—remains a major clinical challenge. To investigate the molecular mechanisms underlying sorafenib resistance in HCC, we established sorafenib-resistant sublines of HepG2 and Huh7 cells through continuous exposure to increasing concentrations of sorafenib. We then performed RNA-seq analysis comparing these resistant sublines with their parental sensitive counterparts. Differential gene expression analysis revealed distinct transcriptional signatures associated with sorafenib resistance. Our findings provide a comprehensive transcriptomic resource for understanding sorafenib resistance mechanisms and identify potential candidate genes that may serve as biomarkers or therapeutic targets for overcoming drug resistance in HCC.

2026-06-10 | GSE322742 | GEO

ARID1B loss drives sorafenib resistance through transcriptional reprogramming in hepatocellular carcinoma

Project description:mRNA-seq was performed in HepG2 hepatocellular carcinoma cells to characterize transcriptional changes driven by ARID1B loss under sorafenib treatment. Wild-type (WT) and ARID1B-knockout (ARID1B-KO) HepG2 cells were treated with sorafenib (5 µM, 48 h) or DMSO vehicle, with three biological replicates per condition. DESeq2 interaction model identified ARID1B-dependent transcriptional responses to sorafenib. Preprint: https://doi.org/10.64898/2026.06.11.731725

2026-06-19 | GSE335769 | GEO

miRNA expression induced by Sorafenib in HepG2 cells and primary human hepatocytes

Project description:miRNA expression induced by Sorafenib in HepG2 cells and primary human hepatocytes

| PRJNA832692 | ENA

Identification and validation of potential key long noncoding RNAs in sorafenib-resistant hepatocellular carcinoma cells

Project description:We report the application of single-molecule-based sequencing technology for high-throughput profiling of lncRNAs expression profile in sorafenib resistant hepatocellular carcinoma cells. We identified 1240 differentially expressed lncRNAs with 576 up-regulated and 664 down-regulated (fold change > 2, P < 0.05) in sorafenib-resistant (HUH7-S) HCC cells (fold change > 2, P < 0.05) in sorafenib-resistant (HepG2-S) HCC cells, compared to parental sorafenib-sensitive (HUH7, HepG2) HCC cells by high-throughput sequencing. In addition, based on GO (Gene Ontology) term enrichment analysis, these differentially expressed lncRNAs are mainly related to binding and catalytic activity and biological regulation of metabolic processes in both the Huh7-S and HepG2-S cell lines compared to parental cell lines. Moreover, the differentially expressed genes analyzed by KEGG (Kyoto Encyclopedia of Genes and Genomes) Pathway were significantly related to tight junction. Among them, TCONS_00284048 and TCONS_00006019 expression were consistently up-regulated in resistant HCC cells, whereas both of them knock down increased the sensitivity of Huh7-S and HepG2-S cells to sorafenib.

2020-02-02 | GSE140202 | GEO

Protein lactylation of citrate synthase promotes the AKI–CKD transition by activating the NLRP3 inflammasome.

Project description:<p>Interstitial renal inflammation contributes to the transition from acute kidney injury (AKI) to chronic kidney disease (CKD). Recently, protein lactylation modification has emerged as a novel mechanism for mediating chronic organ damage. We investigated lactylated protein profiles and the role of protein lactylation during AKI progression. Severe and moderate AKI mouse models were constructed by bilateral renal ischemia for 35 and 25 min, respectively. Lactylation enhancers and inhibitors were used to verify the effect of protein lactylation. Lactylated proteomics was used to detect lactylated protein changes in kidneys, and the lactylated proteins related to kidney injury were screened for verification. We observed significantly higher lactate and protein lactylation levels in the severe AKI model than in the moderate AKI model 1-28 days post-injury. Inhibition of protein lactylation protects against renal interstitial fibrosis. In vitro and in vivo experiments demonstrated that protein lactylation activated Nod-like receptor protein 3 (NLRP3) inflammasomes, promoting the AKI-CKD transition. Comprehensive lactylome profiling of severe AKI models revealed a role for lactylated proteins in metabolic pathways, primarily the tricarboxylic acid (TCA) cycle, where the rate-limiting enzyme, citrate synthase (CS), exhibited significantly elevated lactylation levels 3-7 days post-AKI induction; K370 was the most significant lysine residue. In vitro, following hypoxia/reoxygenation, the modified/lactylated K370T group significantly decreased CS activity and mitochondrial function. Furthermore, CS-K370 lactylation activated the NLRP3 inflammasomes. Thus, lactylation of CS promotes the AKI-CKD transition through NLRP3 inflammasome activation. Inhibition of CS lactylation shows therapeutic potential for preventing this transition.</p>

2025-06-17 | MTBLS12606 | MetaboLights

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data